Santen Pharmaceutical , Ltd. Profit Margin

Santen Pharmaceutical , Ltd. (SNPHY) currently reports a profit margin of 13.26% as of June 2026. That compares with 10.72% in the prior-year period — up 23.8% year over year. That is above the sector sector average of 13.16%. Use the charts on this page to explore Santen Pharmaceutical , Ltd.'s profit margin history and peer comparisons.

Santen Pharmaceutical , Ltd.'s profit margin increased from 10.72% to 13.26% — a 23.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Santen Pharmaceutical , Ltd.'s profit margin of 13.26% is higher than the its sector sector average of 13.16%. That is roughly 0.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Santen Pharmaceutical , Ltd.'s current 13.26% should be judged against industry norms (sector average: 13.16%) and against SNPHY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 13.26%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.16%. From there, open related valuation or income-statement pages for Santen Pharmaceutical , Ltd., and consider following SNPHY for alerts when major investors trade the stock.